

Kura Oncology launches Caspian Therapeutics with $50 million financing to advance menin inhibitor for diabetes and cardiometabolic diseases.
You can purchase shares of Kura Oncology (NASDAQ:KURA) through any online brokerage.
Other companies in Kura Oncology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Kura Oncology has a consensus price target of $24.50.
The stock price for Kura Oncology (NASDAQ: KURA) is $9.72 last updated October 27, 2026 at 12:53 PM EDT.
There are no upcoming dividends for Kura Oncology.
Kura Oncology does not have any upcoming earnings scheduled.
There is no upcoming split for Kura Oncology.
Kura Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling...